GPM-SR 2 Tablet is a combination oral hypoglycemic agent containing Glimepiride 2 mg, Metformin 500 mg, and Pioglitazone 15 mg, indicated for the management of type 2 diabetes mellitus. This formulation leverages the complementary mechanisms of its active ingredients to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates the transcription of insulin-responsive genes involved in glucose and lipid metabolism. The sustained-release formulation ensures a gradual and prolonged drug release, promoting better patient compliance and stable plasma drug concentrations. GPM-SR 2 Tablet is indicated as adjunctive therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes inadequately controlled by monotherapy or dual therapy. Caution is advised in patients with hepatic, renal, or cardiac impairment, and regular monitoring of blood glucose, liver function, and hematologic parameters is recommended. This combination therapy should be prescribed and monitored by healthcare professionals to optimize efficacy and minimize adverse effects.